Biosimilar News: Two Approvals in Europe, Celltrion USA Signs Agreement with Express Scripts
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Wezenla (ustekinumab) for the treatment of plaque psoriasis, including pediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease. The Group also gave its nod to tofidence (tocilizumab) for the treatment of rheumatoid arthritis, COVID-19, polyarticular juvenile idiopathic arthritis, and systemic juvenile […]